Viking Therapeutics Inc VKTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026
-
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm
-
A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up
-
As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22
-
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
-
Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer
-
Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026
-
Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026
Trading Information
- Previous Close Price
- $37.95
- Day Range
- $37.05–38.16
- 52-Week Range
- $22.96–43.15
- Bid/Ask
- $37.20 / $37.50
- Shares Outstanding
- 116.11M
- Market Cap
- $4.33B
- Volume/Avg
- 1M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 59
Valuation
|
Metric
|
VKTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 8.76 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VKTX
|
|---|---|
Quick Ratio | 5.67 |
Current Ratio | 5.72 |
Interest Coverage | — |
Quick Ratio
VKTX
Profitability
|
Metric
|
VKTX
|
|---|---|
Return on Assets (Normalized) | −57.54% |
Return on Equity (Normalized) | −61.85% |
Return on Invested Capital (Normalized) | −66.04% |
Return on Assets
VKTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|plK!^#f | LOCK|^tN?< | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Mcb$J&> | LOCK|TLW@s | $71B | |||
| argenx SE ADR
ARGX
| LOCK|<#ZL$F | LOCK|tPw | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|X!t?sZ | LOCK|Sv$ | $37B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|MC>?Lv$ | LOCK|%wFv | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Bcbb$Hq | LOCK|mqT!m | $26B | |||
| Moderna Inc
MRNA
| LOCK|!tgNV<< | LOCK|Y% | $24B | |||
| Incyte Corp
INCY
| LOCK|$&#s#pJ | LOCK|fgh | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|yyD#Kv^ | LOCK|hZg | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|ttp&!Hv | LOCK|BDP | $16B |
United States